The influence of human N-acetyltransferase genotype on the early bactericidal activity of isoniazid

Clinical Infectious Diseases

Volumn 39, Issue 10, 2004, Pages 1425-1430

  Donald, P R ^a,b   Sirgel, F A ^a   Venter, A ^a   Parkin, D P ^a   Seifart, H I ^a   Van De Wal, B W ^b   Werely, C ^a   Van Helden, P D ^a   Maritz, J S ^c  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b UNIVERSITY OF STELLENBOSCH   (South Africa)

^c Biostatist U S African Med R C   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; ISONIAZID;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACETYLATION; DRUG BLOOD LEVEL; DRUG ELIMINATION; FEMALE; GENOTYPE; HOMOZYGOSITY; HUMAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; SPUTUM CULTURE;

ADOLESCENT; ADULT; ANTITUBERCULAR AGENTS; ARYLAMINE N-ACETYLTRANSFERASE; FEMALE; GENOTYPE; HUMANS; ISONIAZID; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; TIME FACTORS; TUBERCULOSIS, PULMONARY;

EID: 8744272615     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/424999     Document Type: Article

References (20)

1. American Thoracic Society, Centers for Disease Control and Prevention, Infectious Diseases Society of America. Treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167:603-62.
2. Mitchison DA. Role of individual drugs in the chemotherapy of tuberculosis. Int J Tuberc Lung Dis 2000; 4:796-804.
3. Weber WW, Hein DW. Clinical pharmacokinetics of isoniazid. Clin Pharmacokinetics 1979; 4:401-22.
4. Parkin DP, Vandenplas S, Botha FJH, et al. Trimodality of isoniazid elimination. Am J Respir Crit Care Med 1997; 155:1717-22.
5. Ellard GA. The potential clinical significance of the isoniazid acetylator phenotype in the treatment of pulmonary tuberculosis. Tubercle 1984; 65:211-27.
6. Jindani A, Aber VR, Edwards EA, Mitchison DA. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis 1980; 121:939-49.
7. Mitchison DA, Sturm AW. The measurement of early bactericidal activity. In: Malin A, McAdam KPWJ, eds. Bailière's clinical infectious diseases: mycobacterial diseases part II. London: Bailliere, 1997:185-206.
8. Donald PR, Sirgel FA, Venter A, et al. Early bactericidal activity of antituberculosis agents. Expert Rev Anti Infect Ther 2003; 1:141-55.
9. Donald PR, Sirgel FA, Botha FJH, et al. The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis. Am J Respir Crit Care Med 1997; 156:895-900.
10. Ellard GA, Greenfield C. A sensitive urine-test for monitoring the ingestion of isoniazid. J Clin Path 1977; 30:84-7.
11. Donald PR, Sirgel FA, Venter A, et al. The early bactericidal activity of streptomycin. Int J Tuberc Lung Dis 2002; 6:693-8.
12. Seifart HI, Gent WI, Parkin DP, van Jaarsveld PP, Donald PR. High-performance liquid chromatographic determination of isoniazid, acetylisoniazid and hydrazine in biological fluids. J Chromatogr B Biomed Appl 1995; 674:269-75.
13. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16:1215.
14. Hettmansperger TP. Statistical inference based on ranks. New York: John Wiley & Sons, 1984.
15. MINITAB reference manual. State College, PA: Minitab, 1995.
16. Trnka L, Mison P, Bartmann K, Otten H. Experimental evaluation of efficacy. In: Bartmann K, ed. Handbook of experimental pharmacology: antituberculosis drugs. Vol. 84. Berlin: Springer-Verlag, 1988:31-232.
17. Peloquin CA, Nita AT, Burman WJ, et al. Low antituberculosis drug concentrations in patients with AIDS. Ann Pharmacother 1996; 30:919-25.
18. Mitchison DA. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int J Tuberc Lung Dis 1998; 2:10-5.
19. Weiner M, Burman W, Vernon A, et al. Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. Am J Respir Crit Care Med 2003; 167:1341-7.
20. Teo SK. Assessment of a combined preparation of isoniazid, rifampicin and pyrazinamide (Rifater) in the initial phase of chemotherapy in three 6-month regimens for smear-positive pulmonary tuberculosis: a five-year follow-up report. Int J Tuberc Lung Dis 1999; 3:126-32.